USFDA completes inspections at Suven Pharma facilities with no form 483
Hyderabad: Suven Pharma has announced that the US Food & Drug Administration (US FDA) has completed the inspections at the Company's Pashamylaram facilities.
The inspection was conducted from February 12, 2024, to February 23, 2024.
"This is to inform you that our Active Pharmaceutical Ingredients (API) and Formulations facilities (Unit-3 and Unit-5, respectively) in Pashamylaram, Hyderabad, India, have completed the PreApproval Inspections (PAI) and Good Manufacturing Practices (GMP) inspections by the US Food & Drug Administration (US FDA) today," the Company informed in a BSE filing.
Read also: Berhyanda gets DoP nod to acquire up to 76.1 percent stake in Suven Pharma
"We are pleased to inform you that no Form 483 has been issued as a result of the inspection," Suven added.
Read also: Foreign investment of up to Rs 9589 crore in Suven Pharma approved by Cabinet
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.